Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn ...

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span ...

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...

Tectonic Therapeutic (TECX) plunges as Eli Lilly (LLY) ends a mid-stage trial for its kidney drug volenrelaxin which is similar to TECX's lead drug TX45. Read more here.

Leerink notes Eli Lilly (LLY) terminated its volenrelaxin CKD due to failure of a “related heart failure study,” which has caused significant ...

Plus: How AI propelled Nvidia up the list and other insights from this year's survey of corporate reputations.

Healthcare stocks have been under the weather for the past few years, underperforming the broader market’s rally despite ...

We recently compiled a list of the Jim Cramer Discussed These 10 Stocks, AI Power Demand & Healthcare. In this article, we ...